Psoriasis induced by infliximab in a Saudi patient with ankylosing spondylitis

Authors

• Iehab B. Alabed, Department of Internal Medicine, Rheumatology Division, King Fahad Medical City, PO Box 4756, Riyadh, Kingdom of Saudi Arabia. Tel. +966 553460470. Fax. +966 (1) 2889999 Ext. 1395. E-mail: aba1974{at}hotmail.com
• Khalid A. Qushmaq, Department of Internal Medicine, Rheumatology Division, King Fahad Medical City, PO Box 4756, Riyadh, Kingdom of Saudi Arabia. Tel. +966 553460470. Fax. +966 (1) 2889999 Ext. 1395. E-mail: aba1974{at}hotmail.com
• Muhammad A. Khan, Department of Internal Medicine, Rheumatology Division, King Fahad Medical City, PO Box 4756, Riyadh, Kingdom of Saudi Arabia. Tel. +966 553460470. Fax. +966 (1) 2889999 Ext. 1395. E-mail: aba1974{at}hotmail.com

Abstract

Although the therapeutic uses of tumor necrosis factor alpha antagonists have added a highly effective treatment of ankylosing spondylitis and associated spondyloarthropathies, they are associated with many untoward effects. We describe a Saudi patient with ankylosing spondylitis who developed severe psoriatic lesions in treatment with infliximab. He had no personal, or family history of psoriasis, and no other triggering factors known to induce psoriasis.

Article Type

Case Report

First Page

1054

Last Page

1056

Recommended Citation

Alabed, Iehab B.; Qushmaq, Khalid A.; and Khan, Muhammad A. (2010) "Psoriasis induced by infliximab in a Saudi patient with ankylosing spondylitis," Saudi Medical Journal: Vol. 31: Iss. 9, Article 16.
DOI: https://doi.org/10.15537/1658-3175.5127